Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system
In the clinical administration of pralsetinib and selpercatinib, it is crucial to monitor the effects of gender and age on AEs and to be vigilant for unlisted AEs.
Authors
- Qiong Jie
- Jing Li (ORCID: https://orcid.org/0000-0001-9392-6600)
- Li Yang (ORCID: https://orcid.org/0000-0002-3972-4298)
- Yuanyuan Li (ORCID: https://orcid.org/0000-0002-5418-4701)
- Jinjin Chen (ORCID: https://orcid.org/0000-0002-0647-9687)
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.3389/fphar.2024.1424980
- Citations
- 7
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.18
Funders
- Jiangsu Pharmaceutical Association